×
Home Current Archive Editorial board
News Contact
Review paper

Clinical use of an analysis of oxidative stress and IL-6 as the promoters of diabetic polyneuropathy

By
Emina Karahmet Orcid logo ,
Emina Karahmet
Contact Emina Karahmet

Faculty of Pharmacy, University of Tuzla, Tuzla, Bosnia and Herzegovina

Besim Prnjavorac ,
Besim Prnjavorac
Contact Besim Prnjavorac

General Hospital, Tešanj, Tešanj, Bosnia and Herzegovina

Department of Pathophysiology, Faculty of Pharmacy, Sarajevo, Bosnia and Herzegovina

Tamer Bego ,
Tamer Bego

Department of Clinical Biochemistry, Faculty of Pharmacy, Sarajevo, Bosnia and Herzegovina

Adaleta Softić ,
Adaleta Softić

Department of Biochemistry, University of Tuzla, Tuzla, Bosnia and Herzegovina

Lejla Begić ,
Lejla Begić

Department of Biochemistry, Faculty of Pharmacy, University of Tuzla, Tuzla, Bosnia and Herzegovina

Edin Begić ,
Edin Begić

Department of Cardiology, General Hospital "Prim.dr. Abdulah Nakaš", Sarajevo, Bosnia and Herzegovina

Department of Pharmacology, School of Medicine, Sarajevo School of Science and Technology, Sarajevo, Bosnia and Herzegovina

Esma Karahmet ,
Esma Karahmet

Department of Clinical Biochemistry, Faculty of Pharmacy, Sarajevo, Bosnia and Herzegovina

Lejla Prnjavorac ,
Lejla Prnjavorac

General Hospital, Tešanj, Tešanj, Bosnia and Herzegovina

Irfan Prnjavorac
Irfan Prnjavorac

General Hospital, Tešanj, Tešanj, Bosnia and Herzegovina

Abstract

Aim
To investigate interleukin 6 (IL-6) values depending on duration of diabetes mellitus (DM) and evaluate possible correlation
with diabetic polyneuropathy.
Methods
The research study included 90 patients with DM divided into three groups (30 patients each) according to the duration
of DM: group A – patients who had DM for less than 10 years, group B - duration of DM was 10 to 20 years, and group C - patients with DM over 20 years. Control group (K) included 30 healthy participants.
Results
IL-6 was significantly higher in the healthy control group, 180.318 pg/mL±94.18, than in group A, 47.23pg/ml±34.8, group B, 43.31pg/ml±33.17, and group C, 70.39 pg/ml±59.26 (p=0.0001). All groups had significantly different values of IL-6 between each other (p=0.0001). Level of IL-6 was in correlation with diabetic polyneuropathy in the group A (the youngest participants) (p=0.0001). In other groups there was no significant correlation between IL-6 and diabetic polyneuropathy.
Conclusion
The level of IL-6 was in correlation with neuropathy among younger patients. A higher level of IL-6 in the control group
than in diabetic groups is a sign of stronger inflammatory response among younger and healthy people than in patients with DM. 

References

1.
Russell J, Zilliox L. Diabetic neuropathies. Continuum. Minneap Minn). 2014. p. 1226–40.
2.
Volmer-Thole M, Lobmann R. Neuropathy and diabetic foot syndrome. Int J Mol Sci. 2016. p. 917.
3.
Mallet ML, Hadjivassiliou M. Ptolemaios Georgios arrigiannis, Panagiotis Zis. The role of oxidative stress in peripheral neuropathy. J Mol Neurosci. 2020. p. 1009–17.
4.
Morali G, Salamone P, Casale F, Fuda G, Cugnasco P, Carosi C, et al. NADPH oxidase 2 (NOX2) enzyme activation in patients with Chronic Inflammatory demyelinating Polyneuropathy. Eur J Neurol. 2016. p. 958–63.
5.
Villegas-Rivera G, Román-Pintos M, L, Cardona-Muñoz G, Arias-Carvajal E, O, et al. Effects of zetimibe/simvastatin and rosuvastatin on oxidative stress in diabetic neuropathy: A randomized, double-blind. 2015. p. 75–62.
6.
Klermm C, Ch B, Kruchten A, Niemann S, Loffler B, Peters G, et al. Mitogen activated protein kinases (MAPKs) regulate IL-6 over-production during concomitant influenza virus and staphylococcus aureus infection. Nature. 2017. p. 424–57.
7.
Bastard J, Jardel C, Delattre J, Hainque B, Bruckert E, Oberlin F. Evidence for a link between adipose tissue interleukin-6 content and serum C-reactive protein concentrations in obese subjects. Circulation. 1999. p. 2221–2.
8.
Febbraio M, Pedersen B. Contraction-induced myokine production and release: is skeletal muscle an endocrine organ? Ex. Sport Sci. 2005. p. 114–9.
9.
Kristiansen O, Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes. 2005.
10.
Louis E, Raue U, Yang Y, Jemiolo B, Trappe S. Time course of proteolytic, cytokine, and myostatin gene expression after acute exercise in human skeletal muscle. J Appl Physiol. 1985. p. 1744–51.
11.
Ziegler D, Bucholz S, Sohr C, Norrouc Z. Oxidative stress predicts peripheral and cardiac autonomic nerve dysfunction over 6 years in diabetic patients. Acta Diabetol. 2015. p. 65–72.
12.
Cho N, Shaw J, J, Karuranga S, Huang S, Y, et al. IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diab Res and Clin Practice. 2018. p. 271–81.
13.
Vacante M, Malaguarnera M, Motta M. Revision of the ADA-classification of diabetes mellitus type 2 (DMT2): the importance of maturity onset diabetes (MOD), and senile diabetes (DS). Arch Gerontol Res. 2018. p. 113–9.
14.
Diagnosis and classification of diabetes mellitus. Diabetes Care. American Diabetes Association; 2010. p. 62–9.
15.
Tesfaye S, Boulton A, Dyck P, Freeman R, Horowitz M, Kempler P, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010. p. 2285–93.
16.
Herman W, Pop-Busui R, Barffett B, Martin C, Cleary P, Albers J. Use of the Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in Type 1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications. Diabet Med. 2012. p. 937–44.
17.
Park J, Kim D. The necessity of the simple tests for diabetic peripheral neuropathy in type 2 Diabetes Mellitus patients without neuropathic symptoms in clinical practice. J Diabetes Metab J. 2018. p. 442–6.
18.
Kaplan Y, Kurt S, Ünaldi K, Erkorkmaz H, Ü. Risk factors for diabetic polyneuropathy. Noro Psikiyatr Ars. 2014. p. 11–4.
19.
Rashad N, El-Shabrawy R, Sabry H, Fathy H, Said D, Yousef M. Interleukin-6 and hs-CRP as early diagnostic biomarkers for obesity-related peripheral polyneuropathy in non-diabetic patients. Egypt J Immunol. 2018. p. 153–65.
20.
Tuttolomondo A, Placa L, S, Raimondo D, D, Ch B, et al. Adiponectin, resistin and IL-6 plasma levels in subjects with diabetic foot and possible correlations with clinical variables and cardiovascular co-morbidity. Cardiovasc Diabetol. 2010. p. 50.
21.
Skyler J, Bakris G, Bonifacio E, Darsow T, Eckel R, Groop L, et al. Differentiation of diabetes by pathophysiology, natural history, and prognosis. Diabetes. 2017. p. 241–55.
22.
Artasensi A, Pedretti A, Vistoli G, Fumagalli L. Type 2 diabetes mellitus: a review of multi-target drugs. Molecules. 2020.
23.
Bornstein S, Rubino F, Khunti K, Mingrone G, Hopkins D, Birkenfeld A, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020. p. 546–50.
24.
Pizzino G, Irrera N, Cucinotta M, Pallio G, Mannino F, Arcoraci V, et al. Oxidative stress: harms and benefits for human health. Oxid Med Cell Longev. 2017. p. 8416763.
25.
Akiboye F, Rayman G. Management of Hyperglycemia and diabetes in orthopedic surgery. Curr Diab Rep. 2017. p. 13.
26.
Magrinelli F, Ch B, Romano M, Ruggero S, Toffanin E, Triolo G, et al. The association between serum cytokines and damage to large and small nerve fibers in diabetic peripheral neuropathy. J Diabetes Res. 2015. p. 547834.
27.
Korkmaz P, Koçak H, Onbaşı K, Biçici P, Özmen A, Uyar C, et al. The Role of serum procalcitonin, interleukin-6, and fibrinogen levels in differential diagnosis of diabetic foot ulcer infection. J Diabetes Res. 2018. p. 7104352.
28.
Obradovic S, Begic E, Jankovic S, Romanovic R, Djenic N, Dzudovic B, et al. Association of PC and AT levels in the early phase of STEMI treated with pPCI with LV systolic function and 6-month MACE. Acta Clin Belg. 2020. p. 1–7.
29.
Cox A, Sagot Y, Hedou G, Grek C, Wilkes T, Vinik A, et al. Low-dose pulsatile interleukin-6 as a treatment option for diabetic peripheral neuropathy. Front Endocrinol (Lausanne). 2017. p. 89.
30.
Pop-Russi R, Ang L, Holms C. Inflammation as therapeutic target for diabetic neuropathies. Curr Diab Res. 2016. p. 29.
31.
Herder C, Kannenberg J, Huth C, Heier M, Püttgen M, Tonrad S, et al. Proinflammatory cytokines predict the incidence of progression of distal senso-motor polyneuropathy. KORA F4/FF4 Study. Diab Care. 2017. p. 569–76.
32.
Lehmann H, Burke D, Kuwabara S. Chronic inflammatory demyelinating polyneuropathy update on diagnosis immunopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2019. p. 981–7.
33.
He Q, Dong M, Pan Q, Wang X, Guo L. Correlation between changes in inflammatory cytokines and the combination with hypertension in patients with type 2 Diabetes Mellitus. Minerva Endocrinol. 2019. p. 252–8.
34.
Das A, Kalra S, Tiwaskar M, Bajaj S, Seshadri K, Chowdhury S, et al. Expert Group Consensus Opinion: role of anti-inflammatory agents in the management of type 2 diabetes (T2D). J Assoc Physicians India. 2019. p. 65–74.
35.
Dror E, Dalmas E, Meier D, Wueest S, Thevenet J, Thienel C, et al. Postrprandial macrophage-derived IL-1 stimulates insulin, and both synergistically promote glucose disposal and inflammation. Nat Immunol. 2017. p. 283–92.

Citation

Authors retain copyright. This work is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

 

Article metrics

Google scholar: See link

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.